Striant SR: a novel, effective and convenient testosterone therapy for male hypogonadism.
Striant SR (marketed as Striant in the US) is a novel sustained-release mucoadhesive buccal testosterone tablet for the treatment of male hypogonadism. Striant SR restores serum testosterone concentrations to the physiological range within 4 h of application, and steady-state concentrations are achieved within 24 h of twice-daily dosing. In phase III clinical trials, 87-97% of patients using Striant SR achieved 24-h-averaged serum testosterone concentrations within the normal range. In a comparative study, Striant SR was more likely to restore testosterone concentrations to the physiological range than Andropatch. In a small study, Striant SR produced steady-state testosterone concentrations comparable with those achieved with a testosterone gel (50mg testosterone). Striant SR was well tolerated, with a low incidence of adverse events and a low discontinuation rate (3.5%) due to adverse events in phase III studies. Striant SR is an effective, well-tolerated, convenient and discreet treatment for male hypogonadism.
Korbonits
M
M
Department of Endocrinology, St Bartholomew's Hospital, London, UK.
Kipnes
M
M
Grossman
A B
AB
D000278:Administration, Buccal; D017326:Clinical Trials, Phase III as Topic; D003692:Delayed-Action Preparations; D005782:Gels; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy*; D008297:Male; D013607:Tablets; D013739:Testosterone / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D016896:Treatment Outcome
D003692:Delayed-Action Preparations; D005782:Gels; D013607:Tablets; D013739:Testosterone